AR109958A1 - Lactamas bicíclicas de piridona y sus métodos de uso - Google Patents

Lactamas bicíclicas de piridona y sus métodos de uso

Info

Publication number
AR109958A1
AR109958A1 ARP170102878A ARP170102878A AR109958A1 AR 109958 A1 AR109958 A1 AR 109958A1 AR P170102878 A ARP170102878 A AR P170102878A AR P170102878 A ARP170102878 A AR P170102878A AR 109958 A1 AR109958 A1 AR 109958A1
Authority
AR
Argentina
Prior art keywords
group
ring
alkoxy
cycloalkyl
haloalkyl
Prior art date
Application number
ARP170102878A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR109958A1 publication Critical patent/AR109958A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud proporciona compuestos, composiciones farmacéuticas que incluyen los compuestos y los métodos para usar los compuestos. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ se selecciona entre el grupo que consiste en H, alquilo C₁₋₄ y haloalquilo C₁₋₄; el anillo A es tetrazolilo o un heteroarilo de 5 ó 6 miembros con entre 1 y 3 heteroátomos seleccionados entre el grupo que consiste en nitrógeno, oxígeno y azufre; en donde el anillo A es opcionalmente sustituido por 1 ó 2 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₄, cicloalquilo C₃₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄, haloalcoxi C₁₋₄ y ciano; y en donde, si se sustituye un átomo de nitrógeno en el anillo A, el sustituyente no es halógeno, ciano, o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ con un átomo de oxígeno o de azufre directamente unido al átomo de nitrógeno; el anillo B se selecciona entre el grupo que consiste en fenilo, heteroarilo de 5 ó 6 miembros, cicloalquilo de 3 a 7 miembros, y heterociclilo de 4 a 7 miembros; en donde el anillo B es opcionalmente sustituido por: (a) de 1 a 4 sustituyentes seleccionados entre el grupo que consiste en halógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, tioalquilo C₁₋₆, ciano, fenilo, bencilo, CH₂-(cicloalquilo C₃₋₆), y CH₂CH₂-(cicloalquilo C₃₋₆); en donde, si se sustituye un átomo de nitrógeno en el anillo C, el sustituyente no es halógeno, ciano, o un alcoxi C₁₋₆, haloalcoxi C₁₋₆ o tioalquilo C₁₋₆ con un átomo de oxígeno o de azufre directamente unido al átomo de nitrógeno; (b) de 1 a 2 sustituyentes seleccionados entre el grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, haloalcoxi C₁₋₆, CH₂-(heterociclilo de 4 a 6 miembros), CH₂CH₂-(heterociclilo de 4 a 6 miembros), y heteroarilo insustituido de 5 ó 6 miembros; o (c) dos sustituyentes adyacentes que juntos, forman fenilo, heteroarilo de 5 ó 6 miembros, heterociclilo de 4 a 6 miembros o cicloalquilo C₄₋₆; L se selecciona entre el grupo que consiste en un enlace, O, S, NH, NCH₃, (CH₂)ₘ, CH(CH₃), C(CH₃)₂, CF₂, CH₂O, CH₂S, CH(OH), CH₂NH, y CH₂N(CH₃), o L está ausente de manera tal que el anillo A y el anillo B se fusionen; X se selecciona entre el grupo que consiste en O, S, SO, SO₂, CH₂, C(CH₃)₂, CF₂ y CHCF₃; cada uno de Z¹ a Z⁴ se selecciona, en forma independiente, entre el grupo que consiste en CR², NR³ y C=O; Z⁵ es C o N; en donde solo uno de Z¹ a Z⁴ es C=O; y: (i) si Z¹ es C=O y Z⁵ es N, entonces Z², Z³, Z⁴ son, cada uno CR² y X es CH₂; (ii) si Z¹ es C=O y Z² es N, entonces Z³ y Z⁴ son, cada uno CR² y Z⁵ es C; (iii) si Z² es C=O y Z¹ es NR³, entonces Z³ y Z⁴ son, cada uno CR² y Z⁵ es C; (iv) si Z² es C=O y Z³ es NR³, entonces Z¹ y Z⁴ son, cada uno CR² y Z⁵ es C; (v) si Z³ es C=O y Z² es NR³, entonces Z¹ y Z⁴ son, cada uno CR² y Z⁵ es C; (vi) si Z³ es C=O y Z⁴ es NR³, entonces Z¹ y Z² son, cada uno CR² y Z⁵ es C; (vii) si Z⁴ es C=O y Z³ es NR³, entonces Z¹ y Z² son, cada uno CR² y Z⁵ es C; n es 1 ó 2; R² se selecciona entre el grupo que consiste en H, F, alquilo C₁₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆; R³ se selecciona entre el grupo que consiste en H, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, cicloalquilo C₃₋₆,-C(R⁴)₂-cicloalquilo C₃₋₆, heterociclilo de 4 a 6 miembros, y -C(R⁴)₂-(heterociclilo de 4 a 6 miembros); y cada R⁴ se selecciona, en forma independiente, entre el grupo que consiste en H, F, alquilo C₁₋₆, alcoxi C₁₋₆, y haloalquilo C₁₋₆; siempre que, si el anillo B es tetrazolilo, L se seleccione entre el grupo que consiste en CH₂, CH(CH₃), C(CH₃)₂, CF₂; y el anillo C es fenilo.
ARP170102878A 2016-10-17 2017-10-17 Lactamas bicíclicas de piridona y sus métodos de uso AR109958A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662409214P 2016-10-17 2016-10-17

Publications (1)

Publication Number Publication Date
AR109958A1 true AR109958A1 (es) 2019-02-06

Family

ID=60191355

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102878A AR109958A1 (es) 2016-10-17 2017-10-17 Lactamas bicíclicas de piridona y sus métodos de uso

Country Status (7)

Country Link
US (2) US10947226B2 (es)
EP (1) EP3526219B1 (es)
JP (1) JP7349359B2 (es)
CN (1) CN109843886B (es)
AR (1) AR109958A1 (es)
TW (1) TW201821424A (es)
WO (1) WO2018073193A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016287581B2 (en) 2015-07-02 2019-06-06 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017069279A1 (ja) 2015-10-23 2017-04-27 武田薬品工業株式会社 複素環化合物
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EP3526219B1 (en) * 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物
DK3788044T3 (da) 2018-05-03 2023-10-02 Rigel Pharmaceuticals Inc RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
FI3788045T3 (fi) 2018-05-03 2023-06-28 Rigel Pharmaceuticals Inc RIP1-inhibitorisia yhdisteitä ja samojen valmistus- ja käyttömenetelmiä
JP2022511213A (ja) * 2018-06-26 2022-01-31 シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ 細胞壊死阻害剤、その調製方法およびその使用
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
KR20220042431A (ko) 2019-09-06 2022-04-05 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 키나제 억제제
US11753381B2 (en) 2019-09-27 2023-09-12 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase I for the treatment of disease
CN115298184A (zh) 2019-11-07 2022-11-04 里格尔药品股份有限公司 杂环rip1抑制化合物
CN114981248A (zh) * 2019-11-26 2022-08-30 德州大学系统董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
WO2021173917A1 (en) * 2020-02-28 2021-09-02 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
CN115246796A (zh) * 2021-04-27 2022-10-28 中国科学院上海有机化学研究所 一种抑制细胞程序性死亡的化合物及其制备方法
WO2023020486A1 (zh) * 2021-08-17 2023-02-23 广州市恒诺康医药科技有限公司 Rip1激酶抑制剂类化合物及其组合物和用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5206234A (en) 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
CA2141216A1 (en) 1992-07-27 1994-02-03 Michael J. Micklus Targeting of liposomes to the blood-brain barrier
DE69736984T2 (de) 1996-12-06 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des interleukin-1-beta konvertierenden enzyms
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20030113782A1 (en) 2001-11-26 2003-06-19 Karim Felix D. MAP4Ks as modifiers of branching morphogenesis and methods of use
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
WO2004037986A2 (en) 2002-10-23 2004-05-06 Exelixis, Inc. Map2k6 as modifier of branching morphogenensis and methods of use
KR101111477B1 (ko) 2002-12-03 2012-02-23 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 치료제와 연결된 콜레스테롤을 포함하는 접합체
US20050089473A1 (en) 2003-09-10 2005-04-28 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
KR20080090484A (ko) 2005-12-30 2008-10-08 메르크 파텐트 게엠베하 ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체
CA2658573A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8507488B2 (en) 2008-05-13 2013-08-13 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
US20140357570A1 (en) 2011-10-21 2014-12-04 Massachusetts Eye And Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
US9611224B2 (en) 2012-07-13 2017-04-04 Hoffmann-La Roche Inc. Antiproliferative benzo [B] azepin-2-ones
US9394263B2 (en) 2012-08-09 2016-07-19 F. Hoffmann-La Roche Ag Substituted hetero-azepinones
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
EP2986317A4 (en) 2013-04-15 2016-10-05 Yeda Res & Dev INHIBITION OF RIP KINASES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
CN106573006A (zh) 2014-08-21 2017-04-19 葛兰素史密斯克莱知识产权发展有限公司 作为药物的rip1激酶抑制剂杂环酰胺
MX2017016788A (es) 2015-07-02 2018-07-06 Janssen Sciences Ireland Uc Compuestos antibacterianos.
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016287581B2 (en) 2015-07-02 2019-06-06 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
US10709692B2 (en) 2015-12-04 2020-07-14 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
AR107044A1 (es) 2015-12-17 2018-03-14 Astex Therapeutics Ltd Compuesto de quinolin-3-carboxamida, composición farmacéutica que lo comprende y su uso para prepararla
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CA3009324A1 (en) 2015-12-23 2017-06-29 President And Fellows Of Harvard College Cortistatin analogs and uses thereof
WO2017136727A2 (en) 2016-02-05 2017-08-10 Denali Therapeutics Inc. Compounds, compositions and methods
EP3526219B1 (en) * 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP7398391B2 (ja) 2018-04-20 2023-12-14 エフ． ホフマン－ラ ロシュ アーゲー Ｎ－［４－オキソ－２，３－ジヒドロ－１，５－ベンズオキサゼピン－３－イル］－５，６－ジヒドロ－４Ｈ－ピロロ［１，２－ｂ］ピラゾール－２－カルボキサミド誘導体及び例えば過敏性腸症候群（ＩＢＳ）を処置するためのＲＩＰ１キナーゼ阻害剤としての関連化合物

Also Published As

Publication number Publication date
WO2018073193A1 (en) 2018-04-26
US20210163475A1 (en) 2021-06-03
EP3526219A1 (en) 2019-08-21
TW201821424A (zh) 2018-06-16
US20190241565A1 (en) 2019-08-08
JP7349359B2 (ja) 2023-09-22
JP2019530726A (ja) 2019-10-24
EP3526219B1 (en) 2021-12-15
CN109843886B (zh) 2022-04-19
US10947226B2 (en) 2021-03-16
CN109843886A (zh) 2019-06-04

Similar Documents

Publication Publication Date Title
AR109958A1 (es) Lactamas bicíclicas de piridona y sus métodos de uso
AR112338A2 (es) Arilciclohexiléteres de dihidro-tetraazabenzoazuleno
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR109438A1 (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
AR104716A1 (es) Agonistas de triazol del receptor apj
ES2393824T3 (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
AR091176A1 (es) Pirrodilina-2-carboxamidas sustituidas
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
AR088449A1 (es) Benzilindazoles sustituidos
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR120896A1 (es) COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
AR069813A1 (es) Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento
AR113931A1 (es) Tratamientos de combinación que comprenden la administración de 1h-pirazolo[4,3-b]piridinas
CO6260066A2 (es) Derivados de azetidina y su uso como antagonistas de prostaglandina e2
AR113811A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
AR089297A1 (es) Uso de derivados de diamida antranilicos con sustituyentes heteroaromaticos y heterociclicos en combinacion con un agente de control biologico

Legal Events

Date Code Title Description
FB Suspension of granting procedure